The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents. The details were published by the European Patent Office (EPO) when the 2020 official data relating to the number of patent applications was released.
This is a significant milestone for Chiesi, which submitted a total of 38 applications to the EPO over the course of 2020. It was also achieved as a result of the Group’s well-defined strategy aimed at consolidating patent cover to protect its numerous Research & Development projects.
As Antonio Campinos, President of the EPO, explains: “Despite the fact that Italy is one of the countries hit hardest by the pandemic, its companies and inventors managed to file a record number of patent applications in 2020” and "This is no easy task, and it is encouraging news because we know that research and science will ensure a more sustainable world and that innovation is the driving force behind economic recovery".
Although 2020 was a difficult and challenging year, it was not able to halt our ability to innovate, and nonetheless generated significant results both for Italy and the Chiesi Group.
“We are proud to have reached this milestone, which above all represents a constant commitment to Research and Development for our Group, with the aim of improving the quality of life of people all over the world – commented Ugo Di Francesco, CEO of the Chiesi Group -. A commitment for which our thanks go to more than 900 Chiesi researchers at the Group’s 7 research centres in Parma (Italy), France, the UK, Sweden, the US, Canada and China”.